Drugs / MSLN CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07399769 | Jan 2024 → Jan 2027 expected | — | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSLN CAR-T | “MSLN CAR-T cells will be administered as a single intravenous infusion at a total dose of 0.5-2 × 10\^6 CAR-T cells/kg.” NCT07399769 ↗ |
| Modality | Cell therapy | “MSLN-targeted CAR-T cell therapy” NCT07399769 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT07399769 ↗ |
| Target | MSLN | “MSLN-targeted CAR-T cell therapy” NCT07399769 ↗ |